3[3]van Waalwijk van Doorn ESC,Ambergen AW,Janknegt RA.Detrusor activity index:quantification of detrusor overactivity by ambulatory monitoring[J].J Urol,1997,157:596.
4[4]Yokoyama O,Komatsu K,Kodama K,et al.Diagnostic value of intravesical lidocaine for overactive bladder[J].J Urol,2000,164(2):340.
5[5]Gleason DG,Susset J,White C,et al.Evalution of a new once daily formulation of oxybutinin for the treatment of urinary urge incontinence[J].Urology,1999,54:420.
6[6]Hooper P,Tincello DG,Richmond DH.The use of Salivary stimulant pastilles to improve compliance in woman taking oxybutynin hydrochloride for detrusor instability:a pilot study[J].Br J Urol,1997,80:414.
7[7]Appell RA.Clinical efficacy and safety of tolterodine in the treatment of overactive bladder:a pooled analysis[J].Urology,1997,50(Suppl 6A):90.
8[8]Rosario DJ,Cutinha PE,Chapple CR,et al.The effects of single dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability[J].Eur Urol,1996,30(Suppl 2):240.
9[9]Lawson K.Is there a therapeutic future for "potassium channel openers"[J].Clin Sci(Lond),1996,91:651.
10[10]Yasuhiko I,Yoshinobu Y,Hiroo T,et al.Relaxant effects of isoproterenol and selective β3-adrenoceptor agonists on normal,low compliant and hyperreflexic human bladders[J].J Urol,2001,165:240.
